Estònia - estonià - Ravimiamet

sanofi pasteur s.a. - meningokokk a,c, bivalentne puhastatud polüsahhariidantigeen - süstelahuse pulber ja lahusti - 1tk

Estònia - estonià - Ravimiamet

sanofi winthrop industrie - amisulpriid - tablett - 200mg 150tk; 200mg 30tk

Estònia - estonià - Ravimiamet

sanofi-aventis estonia oÜ - spiramütsiin - õhukese polümeerikattega tablett - 3000000rÜ 10tk

Estònia - estonià - Ravimiamet

sanofi winthrop industrie - furosemiid - toimeainet prolongeeritult vabastav kõvakapsel - 60mg 30tk

Estònia - estonià - Ravimiamet

sanofi-aventis groupe - adenosiin - süstelahus - 3mg 1ml 2ml 6tk

Estònia - estonià - Ravimiamet

sanofi pasteur s.a. - bcg bakterid - intravesikaalsuspensiooni pulber - 81mg 1tk

Unió Europea - estonià - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - gripp, inimene - vaktsiinid - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Unió Europea - estonià - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glükogeeni ladustamise ii tüüpi haigused - muud alimentary seedetrakti ja ainevahetust tooted, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Unió Europea - estonià - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - muud alimentary seedetrakti ja ainevahetust tooted, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Unió Europea - estonià - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - hulgiskleroos - selektiivsed immunosupressandid - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).